

Determination of Bioactive Compounds in Edible Mushroom *Pleurotus eryngii*

Keshamma E

Associate Professor, Department of Biochemistry, Maharani Cluster University, Palace Road,
Bengaluru-560 001, Karnataka, India

ABSTRACT

The current study designed to conduct with the main purpose to determine bioactive components of methanolic extract of edible oyster mushroom *viz.* *Pleurotus eryngii* using GC-MS technique. *P. eryngii* samples was purchased from local market, and subjected to methanolic extraction using Soxhlet extraction method. The results of GC-MS analysis delineated that the following prevailing bioactive compounds identified in the methanolic extract of *P. eryngii* i.e., conhydrin, diethyl phthalate, phthalic acid-butyl hex-3-yl ester (alkaloids), ar-turmerone (sesquiterpenoid), palmitic acid, myristic acid, phenol, and benzoic acid. In conclusion, polyphenols, alkaloids, terpenoids and Vitamin B class of secondary metabolites are the majorly identified in GC-MS analysis of methanolic extracts of *P. eryngii*. Therefore, methanolic extract of *P. eryngii* could be exploited for biopharmaceutical and therapeutic applications.

Keywords: Methanolic extracts. *P. eryngii*, Therapeutic, Biopharmaceutical applications

1. Introduction

Due to recent advancements in technologies and greater realization of mushroom nutrient values, mushrooms have occupied an important place in food in several parts of the world ^[1]. Researches on the nutritive value of edible mushrooms indicate that they may be regarded as healthy foods, even though they are deficient in calories & fat and consist of about 90% water ^[2-4]. Mushrooms have been reported to be of therapeutic value, useful in preventing diseases such as hypertension, hypercholesterolemia, cancer and also having antibacterial and antiviral properties. These functional characteristics are mainly due to their chemical composition.⁵⁻⁷ Scientific experiments revealed that of Shitake mushrooms such as *Lentinus edode*, *Grifola froudosa*, *Agaricus bisporus* and oyster mushrooms serve as natural repositories of Vitamin-B such as niacin, flavin and pyridoxine,⁸ and organic acids such as the glucons, monoterpenoids, and diterpenoids, lipids, proteins such as hydrophobins and trace elements such as selenium ^[9,10].

Obesity results from an imbalance involving excessive calorie consumption and/or inadequate physical activity. It is a complex health issue involving a variety of factors *viz.* metabolism, behavior, environment, genetics, etc... The prevalence of obesity is growing at a dreadful rate. The population of worldwide obesity in 2011 has been more than doubled as compared to the population in 1980 ^[11]. Obesity is considered to be a major risk factor contributing too many chronic diseases, such as type-2 diabetes, cardiovascular diseases and certain cancers. Thus, effective ways of preventing and treating obesity are required.

Pancreatic lipase plays an important role in the digestion of dietary fat. It hydrolyzes and converts dietary triglycerols into monoglycerides and free fatty acids. Orlistat, a hydrogenated derivative of lipstatin derived from *Streptomyces toxitricini*, is a potent inhibitor of gastric, pancreatic and carboxyl ester lipase and has proved to be effective for the treatment of human obesity. Sibutramine (a monoamine reuptake inhibitor) and rimonabant (an endocannabinoid receptor blocker) are the other pancreatic lipase inhibitors used in the treatment of human obesity ^[12]. However, obese and specially overweighed population is reluctant to assume obesity as a medical problem, and therefore before turning to a health professional, starts his/her own therapy by using special foods, such as reduced fat content (light) products and nutritional supplements (including herbal extracts) and more often, diets without scientific evidence. Therefore, foods containing active principles with clear metabolic targets and scientific evidence of their activity may help in the self-fight against obesity, reaching to

a higher number of individuals and in an earlier stage of their own obesity. A wide range of natural products (including crude extracts) mainly obtained from plants have been reported as effective pancreatic lipase inhibitors [13-21].

Only a few interesting pancreatic lipase inhibitors were isolated from edible fungi, two of them were β -lactones with unusual configurations named percyquinnin (obtained from *Stereum complicatum*) and vibralactone (*Boreostereum vibrans*) with similar IC_{50} (0.4 Ig mL^{-1}) [18,22]. For a few mushroom species, the observed activities were also effective *in-vivo* according to the results obtained with animal models. Ahn et al reported the anti-obesity effects of *Isaria sinclairii* fruiting bodies [23], and Mizutani et al demonstrated the pancreatic lipase inhibitory activity of water extracts (polysaccharide-rich fraction) obtained from *Pleurotus eryngii* fruiting bodies [24]. Hence, in the present study the methanolic extracts edible oyster mushroom *viz. Pleurotus eryngii* was subjected to GC-MS analysis for the determination of bioactive components.

2. Materials and Methods

2.1 Plant Material and sample preparation

The edible oyster mushroom *viz. Pleurotus eryngii* was purchased from local market and 500 g of the harvested mushroom sample was washed to remove the surface pollutants, dried at 40°C until complete dry and powdered. These samples were subjected for the successive extraction with methanol.

2.2 Extraction Procedure

The mushroom sample was subjected to methanolic extraction. 25 g of powdered sample was filled in a Whatmann filter paper and kept inside tumble. 200 ml of the solvent was added in tumble. The tumble was fit into a round bottom flask containing 700 ml of the solvent and run for 6-8 hours at the temperature based on the boiling point of the respective solvent using soxhlet apparatus. Later the extract was subjected for the distillation for 2-3 hours. These extracts were kept in water bath at 40°C for drying. The dried extracts thus obtained were used for GC-MS analysis [25].

2.3 Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

2.3.1 Sample preparation

Sample was grinded with GC grade methanol, centrifuged and the supernatant was collected and injected into the GC-MS system.

2.3.2 GC-MS instrument setup details

GC-MS analysis was performed using a Shimadzu GC – MS - QP 2010 gas chromatograph system. Gas Chromatograph interfaced to a Mass Spectrometer (GC/MS) equipped with an TG 5MS silica Capillary column (30m×0.25mm ID). \times MDF composed of 5% diphenyl/95% dimethyl polysiloxane with 0.25 μm film thickness. For GC/MS detection, an electron ionization system with ionization energy of 70 eV was used. The oven temperature was programmed from 80°C with a hold of 2 mins and then 200°C at 9°C/min and a hold for 4 min and then to 300°C at 10 °C/min and a hold for 5 min. Helium was used as carrier gas at flow at the flow rate of 1.5 mL/min. The injector temperature was 250°C, injection size 1.0 μL neat, with spitless mode. Injector temperature was 250°C and ion source temperature was 230°C. The interface and MS ion source were maintained at 300°C and 230°C, respectively. Mass spectra were taken at 70 eV; a scan interval of 0.2 seconds and fragments from with a mass scan range of 50-550 amu. Total GC running time was 35 min. The relative percentage amount of each component was calculated by comparing its average peak area to the total areas. Data handling was done using Xcaliber software. The identification of compounds was based on comparison of their mass spectra with those of NIST Libraries. Software adopted to NIST 2014 (2.2.0.0) with AMDIS v.2.72 Version.

3. Results

GC-MS analyses of the methanolic extract of *Pleurotus eryngii* led to the identification of 27 components (Figure 2). The 20 peaks identified account for 100% of the extract and listed along with respective retention time and the percentage of compound in the extract in Table 1.

TABLE 1: Chemical composition of methanolic extract of *Pleurotus eryngii*

| Peak No. | RT | Area (%) | Name of Compound |
|----------|-------|----------|---|
| 1 | 7.99 | 1.36 | Dimethyl Sulfoxide |
| 2 | 11.9 | 0.35 | Benzene, 1,3,5-tris(methoxymethyl) |
| 3 | 12.61 | 0.43 | Phenol |
| 4 | 13.58 | 94.18 | N-Methyl- α -pyrrolidone |
| 5 | 15.92 | 0.71 | Triacetoneamine |
| 6 | 17.26 | 0.46 | Benzoic acid |
| 7 | 19.63 | 0.54 | Conhydrin |
| 8 | 23.24 | 0.47 | Ile-Val-Arg |
| 9 | 23.52 | 0.35 | Fluoroacetic acid, dodecyl ester |
| 10 | 24.88 | 0.5 | L-Glutamine |
| 11 | 26.62 | 0.33 | 2,4-Di-tert-butylphenol |
| 12 | 28.63 | 0.26 | Diethyl Phthalate |
| 13 | 30.28 | 0.25 | aR-Turmerone |
| 14 | 32.24 | 0.28 | Myristic acid |
| 15 | 32.93 | 0.24 | 10-Heneicosene (c,t) |
| 16 | 36.04 | 0.28 | Methtryptoline |
| 17 | 36.1 | 0.3 | Methyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate |
| 18 | 36.34 | 0.38 | Palmitic acid |
| 19 | 36.47 | 0.34 | Phthalic acid, butyl hex-3-yl ester |
| 20 | 37.31 | 0.33 | Indazol-4-one, 3,6,6-trimethyl-1-phthalazin-1-yl-1,5,6,7-tetrahydro |

4. Discussion

The GC-MS results of our study revealed that ethanolic extract of *Pleurotus eryngii* led to the identification of 20 components, and it account for 100% of the extract. The prevailing compounds of ethanolic extract of *Pleurotus eryngii* which have been reported to possess pharmacological potentials *viz.* antiobesity, antimicrobial, antihyperglycemic, antioxidant, anti-inflammatory and anti-carcinogenic in the literature are conhydrin, diethyl phthalate, and phthalic acid-butyl hex-3-yl ester (alkaloids) ^[26], ar-turmerone (sesquiterpenoid) ^[27], palmitic acid, myristic acid, phenol, and benzoic acid ^[28].

Namba et al demonstrated that water extract of *Pleurotus eryngii* reduces pancreatic lipids ^[29]. In another research study conducted by Mizutani et al reported that *Grifola frondosa* inhibits pancreatic lipase by inhibiting hydrolysis of 4-methylumbelliferyl (4-MUO) and trioleoylglycerol emulsified with lecithin ^[24]. Furthermore, Mizutani et al in another study investigated the mechanism underlying anti-lipase activity of *Pleurotus eryngii* extract *in-vitro* and its hypolipidemic property in fat-loaded mice. The results demonstrated that *Pleurotus eryngii* extract suppressed the elevations of plasma and chylomicron triacylglycerol levels and inhibited pancreatic lipase at concentrations of 50-300 μ g/mL, indicating the hypolipidemic effect of *Pleurotus eryngii* extract was owed to pancreatic lipase inhibition resulting in low-absorption of fat. Hence, it was postulated that the possible mechanism of action that ameliorate obesity would be attributed to pancreatic lipase inhibition activities of *Pleurotus eryngii* extract ^[24]. In a study reported by Chen et al the purified *Pleurotus eryngii* polysaccharide performed a strong ability of inhibiting lipid accumulation in foam cells, resulting in only about 28.06% of lipid content left inside the cell compared to 100% in the control ^[30].

The *in-vitro* pancreatic lipase inhibitory activity of methanolic extracts of *Pleurotus eryngii* could be attributed to the prevailing compounds identified in the GC-MS analysis *i.e.* conhydrin, diethyl phthalate, phthalic acid-butyl hex-3-yl ester (alkaloids), ar-turmerone (sesquiterpenoid), palmitic acid, myristic acid, phenol, and benzoic acid from methanol extract of *Pleurotus eryngii*.

CONCLUSION

Polyphenols, alkaloids terpenoids, and Vitamin B class of secondary metabolites majorly identified in GC-MS analysis of methanolic extract of *Pleurotus eryngii* have been reported to possess the *in-vitro* pancreatic lipase inhibitory activities in the literature. Hence, *in-vivo* studies could be recommended to evaluate pancreatic lipase of activities of methanolic extract of *Pleurotus eryngii* could exploited for biopharmaceutical and therapeutic applications.

References

1. Hafiz F, Begum M, Parveen S, Nessa Z, Azad AK. Study of edible mushroom grown on *Eucalyptus Camaldulensis* trunk and under the soil of *Albizia Procera*. In Pakistan J. Nutr 2003.
2. Nylen B, Vara Matsvampar. Naturoch. Kultur/LTs forlag.1985.
3. Manzi P, Gambelli L, Marconi S, Vivanti V, Pizzoferrato L. Nutrients in edible mushrooms: an inter-species comparative study. Food chemistry. 1999 Jun 1;65(4):477-82.
4. Sanmee R, Dell B, Lumyong P, Izumori K, Lumyong S. Nutritive value of popular wild edible mushrooms from northern Thailand. Food chemistry. 2003 Sep 1;82(4):527-32.
5. Crisan EV, Sands A, Chang ST, Hayes WA. The biology and cultivation of edible mushrooms. Nutritional value, New York Academic. 1978:251-93.
6. Chobot V, Opletal L, Jáhodář L, Patel AV, Dacke CG, Blunden G. Ergosta-4, 6, 8, 22-tetraen-3-one from the edible fungus, *Pleurotus ostreatus* (oyster fungus). Phytochemistry. 1997 Aug 1;45(8):1669-71.
7. Manzi P, Aguzzi A, Pizzoferrato L. Nutritional value of mushrooms widely consumed in Italy. Food chemistry. 2001 May 1;73(3):321-5.
8. Sofowora A. Medicinal plants and traditional medicine in Africa. Karthala; 1996.
9. Dikeman CL, Bauer LL, Flickinger EA, Fahey GC. Effects of stage of maturity and cooking on the chemical composition of select mushroom varieties. Journal of Agricultural and Food Chemistry. 2005 Feb 23;53(4):1130-8.
10. Valentão P, Andrade PB, Rangel J, Ribeiro B, Silva BM, Baptista P, Seabra RM. Effect of the conservation procedure on the contents of phenolic compounds and organic acids in chanterelle (*Cantharellus cibarius*) mushroom. Journal of Agricultural and Food Chemistry. 2005 Jun 15;53(12):4925-31.
11. WHO (World Health Organization), (2011). Obesity and Overweight. Retrieved from: <http://www.who.int/mediacentre/factsheets/fs311/en/index.html>. (Accessed on: May 24, 2020).
12. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. The Lancet. 2007 Jan 6;369(9555):71-7.
13. McDougall GJ, Kulkarni NN, Stewart D. Berry polyphenols inhibit pancreatic lipase activity in vitro. Food Chemistry. 2009 Jul 1;115(1):193-9.
14. Morikawa T, Xie Y, Asao Y, Okamoto M, Yamashita C, Muraoka O, Matsuda H, Pongpiriyadacha Y, Yuan D, Yoshikawa M. Oleanane-type triterpene oligoglycosides with pancreatic lipase inhibitory activity from the pericarps of *Sapindus rarak*. Phytochemistry. 2009;70(9):1166-72.
15. Yamada K, Murata T, Kobayashi K, Miyase T, Yoshizaki F. A lipase inhibitor monoterpene and monoterpene glycosides from *Monarda punctata*. Phytochemistry. 2010;71(16):1884-91.
16. Ninomiya K, Matsuda H, Shimoda H, Nishida N, Kasajima N, Yoshino T, Morikawa T, Yoshikawa M. Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorganic & Medicinal Chemistry Letters. 2004;14(8):1943-6.

17. Sharma N, Sharma VK, Seo SY. Screening of some medicinal plants for anti-lipase activity. *Journal of ethnopharmacology*. 2005;97(3):453-6.
18. Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. *Drug discovery today*. 2007;12(19-20):879-89.
19. Slanc P, Doljak B, Mlinarič A, Štrukelj B. Screening of wood damaging fungi and macrofungi for inhibitors of pancreatic lipase. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2004;18(9):758-62.
20. Mahomoodally FM, Ramcharun S. In vitro kinetic of inhibition of lipase, antioxidant activity, glucose entrapment and polyphenolic content of *Solanum linnaeanum*. *Journal of Biologically Active Products from Nature*. 2015 Nov 2;5(6):383-96.
21. Irondi EA, Shode FO, Afolabi WO, Boligon AA. In Vitro Inhibitory Effects of Coconut Husk Extract on Some Enzymes Relevant to the Pathogenesis of Obesity, Gout and Hypertension. *Journal of Biologically Active Products from Nature*. 2017;7(5):358-68.
22. Liu DZ, Wang F, Liao TG, Tang JG, Steglich W, Zhu HJ, Liu JK. Vibralactone: a lipase inhibitor with an unusual fused β -lactone produced by cultures of the basidiomycete *Boreostereum vibrans*. *Organic letters*. 2006 Dec 7;8(25):5749-52.
23. Ahn MY, Jee SD, Lee BM. Antiobesity effects of *Isaria sinclairii* by repeated oral treatment in obese Zucker rats over a 4-month period. *Journal of Toxicology and Environmental Health, Part A*. 2007 Jul 5;70(15-16):1395-401.
24. Mizutani T, Inatomi S, Inazu A, Kawahara E. Hypolipidemic effect of *Pleurotus eryngii* extract in fat-loaded mice. *Journal of nutritional science and vitaminology*. 2010;56(1):48-53.
25. Jose GS, Radhamany PM. In vitro antioxidant activities, total phenolics and flavonoid of wild edible mushroom *Macrolepiota mastoidea* (Fr.) Singer. *Int J Pharm Sci*. 2013;5(2):161-6.
26. Ambika AP, Nair SN. Wound healing activity of plants from the Convolvulaceae family. *Advances in Wound Care*. 2019 Jan 1;8(1):28-37.
27. Lekshmi PC, Arimboor R, Indulekha PS, Nirmala Menon A. Turmeric (*Curcuma longa* L.) volatile oil inhibits key enzymes linked to type 2 diabetes. *International journal of food sciences and nutrition*. 2012 Nov 1;63(7):832-4.
28. Kawser Hossain M, Abdal Dayem A, Han J, Yin Y, Kim K, Kumar Saha S, Yang GM, Choi HY, Cho SG. Molecular mechanisms of the anti-obesity and anti-diabetic properties of flavonoids. *International journal of molecular sciences*. 2016;17(4):569.
29. Namba H. Maitake D-fraction: healing and preventive potential for cancer. *Journal of Orthomolecular Medicine*. 1997;12(1):43-9.
30. Chen J, Yong Y, Xing M, Gu Y, Zhang Z, Zhang S, Lu L. Characterization of polysaccharides with marked inhibitory effect on lipid accumulation in *Pleurotus eryngii*. *Carbohydrate polymers*. 2013;97(2):604-13.